Search results for "Angiogenesis"

showing 10 items of 552 documents

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

Methodological Approach to Use Fresh and Cryopreserved Vessels as Tools to Analyze Pharmacological Modulation of the Angiogenic Growth

2016

The sprouting of new vessels is greatly influenced by the procedure chosen. We sought to optimize the experimental conditions of the angiogenic growth of fresh and cryopreserved vessels cultured in Matrigel with the aim to use this system to analyze the pharmacological modulation of the process. Segments of second-order branches of rat mesenteric resistance arteries, thoracic aorta of rat or mouse, and cryopreserved rat aorta and human femoral arteries were cultured in Matrigel for 7-21 days in different mediums, as well as in the absence of endothelial or adventitia layer. Quantification of the angiogenic growth was performed by either direct measurement of the mean length of the neovessel…

Male0301 basic medicinemedicine.medical_treatmentNeovascularization PhysiologicAorta Thoracic030204 cardiovascular system & hematologycryopreservationFibroblast growth factorhuman vesselsNeovascularizationAndrologyangiogenesisMice03 medical and health scienceschemistry.chemical_compoundOrgan Culture Techniques0302 clinical medicinemedicine.arteryAdventitiamatrigelmedicineAnimalsHumansThoracic aortaRats WistarCryopreservationPharmacologyAortaMatrigelGrowth factorarterial ring assayRatsVascular endothelial growth factorDrug Combinations030104 developmental biologymedicine.anatomical_structurechemistryAdrenergic alpha-1 Receptor Antagonistscardiovascular systemProteoglycansAdrenergic alpha-1 Receptor AgonistsCollagenLamininmedicine.symptomCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology
researchProduct

Enhanced Activity of Meprin-α, a Pro-Migratory and Pro-Angiogenic Protease, in Colorectal Cancer

2011

Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is not known. We investigated the effect of this protease on cell migration and angiogenesis in vitro and studied the expression of meprin-α mRNA, protein and proteolytic activity in primary tumors at progressive stages and in liver metastases of patients with colorectal cancer, as well as inhibitory activity towards meprin-α in sera of cancer patient as compared to healthy controls. We found that the hepatocyte growth factor (HGF)- induced migratory response of meprin-transfected epithelial c…

MaleAngiogenesisColorectal cancerCancer TreatmentGene Expressionlcsh:MedicineBiochemistry0302 clinical medicineCell MovementMolecular Cell BiologyGastrointestinal CancersMorphogenesisPathologylcsh:ScienceAged 80 and over0303 health sciencesMetalloproteinaseMultidisciplinaryHepatocyte Growth FactorLiver NeoplasmsMetalloendopeptidasesMiddle AgedImmunohistochemistryRecombinant ProteinsEnzymes3. Good healthOncology030220 oncology & carcinogenesisMedicineFemaleHepatocyte growth factorAntiangiogenesis TherapyColorectal NeoplasmsResearch Articlemedicine.drugAdultmedicine.medical_specialtyImmunoblottingHistopathologyNeovascularization PhysiologicCell MigrationGastroenterology and HepatologyIn Vitro TechniquesBiologyMannose-Binding LectinCell LineRectal CancerYoung Adult03 medical and health sciencesDogsDiagnostic MedicineInternal medicineGastrointestinal TumorsmedicineAnimalsHumansImmunoprecipitationBiologyAged030304 developmental biologylcsh:RCancers and NeoplasmsCancerPlasminogenBlotting Northernmedicine.diseaseRatsEndocrinologyAnatomical PathologyTumor progressionZymogen activationCancer cellCancer researchlcsh:QDevelopmental BiologyPLoS ONE
researchProduct

Intravitreal ranibizumab treatment of retinal angiomatous proliferation

2010

. Purpose:  To determine the efficacy of intravitreal injections of ranibizumab in the treatment of retinal angiomatous proliferation (RAP) in neovascular age-related macular degeneration. Methods:  Retrospective, consecutive case series of 26 eyes (26 patients) treated with intravitreal injections of 0.5 mg ranibizumab for RAP. Patients received intravitreal injections at monthly intervals during upload phase for a 3-month period. Results:  Mean visual acuity before treatment was 0.75 ± 0.38logMAR (mean ± SD, n = 26). In the upload phase, mean visual acuity improved 4 weeks after the initial injection to 0.6 ± 0.37logMAR (n = 26) and to 0.53 ± 0.34logMAR (n = 26) 4 weeks after the third mo…

MaleAngiomatosismedicine.medical_specialtyVisual acuitygenetic structuresVisual AcuityAngiogenesis InhibitorsFoveal thicknessRetinal NeovascularizationAntibodies Monoclonal Humanizedchemistry.chemical_compoundOpticsRanibizumabOphthalmologymedicineHumansMaintenance phaseAgedRetrospective StudiesAged 80 and overbusiness.industryRetinalGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseeye diseasesOphthalmologyTreatment OutcomechemistryIntravitreal InjectionsRetreatmentWet Macular DegenerationFemalesense organsRanibizumabIntravitreal ranibizumabmedicine.symptombusinessTomography Optical Coherencemedicine.drugActa Ophthalmologica
researchProduct

The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma

2006

Abstract Background Maspin, a member of the serpin family, is a suppressor of tumor growth, an inhibitor of angiogenesis and an inducer of apoptosis. Maspin induces apoptosis by increasing Bax, a member of the Bcl-2 family of apoptosis-regulating proteins. In this exploratory study, we investigated the associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma (IHCCA). Methods Twenty-two paraffin-embedded samples were analyzed by immunohistochemical methods using Maspin, Bax and CD34 antibodies. Maspin was scored semiquantitatively (HSCORE). Apoptosis was assessed using an antibody against cleaved caspase-3. Results The strong relati…

MaleCancer ResearchPathologymedicine.medical_specialtyAngiogenesisApoptosisCaspase 3Kaplan-Meier EstimateSerpinlcsh:RC254-282law.inventionCholangiocarcinomaBcl-2-associated X proteinlawBiomarkers TumorGeneticsmedicineHumansGenes Tumor SuppressorSerpinsIntrahepatic CholangiocarcinomaAgedbcl-2-Associated X ProteinbiologyCaspase 3business.industryMicrocirculationLiver NeoplasmsMaspinMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoplasm ProteinsEnzyme ActivationOncologyApoptosisCancer researchbiology.proteinSuppressorFemalebusinessResearch ArticleBMC Cancer
researchProduct

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

2014

ABSTRACT:  Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. Af…

MaleCancer Researchmedicine.medical_specialtyVatalanibDrug-Related Side Effects and Adverse ReactionsPyridinesMedizinContrast MediaAngiogenesis InhibitorsStable DiseaseText miningCarcinoma Non-Small-Cell LungmedicineHumansIn patientLung cancerAgedNeoplasm StagingClinical Trials as Topicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRadiographyOncologyResponse Evaluation Criteria in Solid TumorsDynamic contrast-enhanced MRIDrug EvaluationPhthalazinesFemaleRadiologyNuclear medicinebusinessProgressive diseaseBiomarkersFuture oncology (London, England)
researchProduct

Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferat…

2010

Abstract Angiotensin II (Ang-II) displays inflammatory activity and is implicated in several cardiovascular disorders. This study evaluates the effect of cis- and trans (t)-resveratrol (RESV) in two in vivo models of vascular inflammation and identifies the cardioprotective mechanisms that underlie them. In vivo, Ang-II–induced arteriolar leukocyte adhesion was inhibited by 71% by t-RESV (2.1 mg/kg, i.v.), but was not affected by cis-RESV. Because estrogens influence the rennin-angiotensin system, chronic treatment with t-RESV (15 mg/kg/day, orally) inhibited ovariectomy-induced arteriolar leukocyte adhesion by 81%, partly through a reduction of cell adhesion molecule (CAM) expression and c…

MaleChemokineEndotheliumOvariectomyImmunologyInflammationAngiogenesis InhibitorsCell CommunicationPharmacologyRats Sprague-DawleyDownregulation and upregulationStilbenesmedicineImmunology and AllergyAnimalsHumansCells CulturedbiologyCell adhesion moleculeMonocyteAngiotensin IINF-kappa BStereoisomerismAngiotensin IIRatsUp-RegulationPPAR gammaDisease Models Animalmedicine.anatomical_structureCardiovascular DiseasesResveratrolImmunologybiology.proteinFemaleEndothelium Vascularmedicine.symptomSignal transductionInflammation MediatorsJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR

2014

Solid tumours are exposed to microenvironmental factors such as hypoxia that normally inhibit cell growth. However, tumour cells are capable of counteracting these signals through mechanisms that are largely unknown. Here we show that the prolyl hydroxylase PHD3 restrains tumour growth in response to microenvironmental cues through the control of EGFR. PHD3 silencing in human gliomas or genetic deletion in a murine high-grade astrocytoma model markedly promotes tumour growth and the ability of tumours to continue growing under unfavourable conditions. The growth-suppressive function of PHD3 is independent of the established PHD3 targets HIF and NF-κB and its hydroxylase activity. Instead, l…

MaleColorectal cancerAngiogenesisProcollagen-Proline DioxygenaseGeneral Physics and AstronomyApoptosisGrowth inhibitoryBiologyArticleGeneral Biochemistry Genetics and Molecular BiologyHypoxia-Inducible Factor-Proline DioxygenasesGene Knockout Techniqueschemistry.chemical_compoundCell Line TumormedicineAnimalsHumansEgfr signalingHypoxiaCell ProliferationMice KnockoutMultidisciplinaryCell growthGeneral ChemistryHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseMolecular biologyErbB ReceptorsOxygenchemistryApoptosisCancer researchFemalemedicine.symptomGrowth inhibitionGlioblastomaNature Communications
researchProduct

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid

2017

OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed …

MaleDegeneracion macular asociada a la edad no neovascularVisual acuityTriamcinolone acetonidegenetic structuresFluido subretinianoAngiogenesis InhibitorsFundus (eye)Triamcinolone0302 clinical medicineDegeneración macular asociada a la edad no neovascular Fluido intrarretiniano Fluido subretiniano Intraretinal fluid Intravitreal therapies Non-neovascular age related macular degeneration Spectral domain optical coherence tomography Subretinal fluid Terapias intravítreas Tomografía de coherencia óptica de dominio espectralFluorescein AngiographyTomografia de coherencia optica de dominio espectralAged 80 and overmedicine.diagnostic_testSubretinal FluidExudates and TransudatesGeneral MedicineFluorescein angiographyFluido intrarretinianoBevacizumabTreatment Outcomemedicine.anatomical_structureIntravitreal InjectionsFemalemedicine.symptomIntravitreal therapiesTomography Optical Coherencemedicine.drugSubretinal fluidmedicine.medical_specialtyBevacizumabRetinal DrusenRetinaSpectral domain optical coherence tomography03 medical and health sciencesNon-neovascular age related macular degenerationRanibizumabOphthalmologymedicineHumansAgedRetinabusiness.industryMacular degenerationmedicine.diseaseTerapias intravitreaseye diseasesSurgeryWet Macular Degeneration030221 ophthalmology & optometryIntraretinal fluidsense organsRanibizumabbusiness030217 neurology & neurosurgeryArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Effectiveness of anti-vascular endothelial growth factors in neovascular age-related macular degeneration and variables associated with visual acuity…

2021

Objective To assess the overall effectiveness of anti-vascular endothelial growth factor (VEGF) therapy in treatment-naïve patients with neovascular age-related macular degeneration (nAMD) in a clinical practice setting. Study design EAGLE was a retrospective, 2-year, cohort observational, multicenter study conducted in Italy that analyzed secondary data of treatment-naïve patients with nAMD. The primary endpoint evaluated the mean annualized number of anti-VEGF injections at Years 1 and 2. The main secondary endpoints analyzed the mean change in visual acuity (VA) from baseline and variables associated with visual outcomes at Years 1 and 2. Results Of the 752 patients enrolled, 745 (99.07…

MaleEaglesAntiVEGF Drugs nAMD clinical practiceVisual AcuitySocial SciencesRetinal NeovascularizationInfographicsGeographical locationsMacular DegenerationMedical ConditionsEndocrinologyRetrospective StudieClinical endpoint80 and overPsychologyAged 80 and overEukaryotaItalyCohortMedicineHumanmedicine.medical_specialtyScienceDrug Administration ScheduleFollow-Up StudieSigns and Symptomsbiology.animalLinear regressionHumansAgedRetrospective StudiesSettore MED/30 - Malattie Apparato VisivoData VisualizationOrganismsBiology and Life Sciencesmedicine.diseaseOphthalmologyMacular DisordersLesionsEyesObservational studyClinical MedicinePeople and placesNeuroscienceVascular Endothelial Growth Factor AVisual acuityTime FactorsEye DiseasesVisionPhysiologyAngiogenesis InhibitorsMedicine and Health SciencesGeriatric OphthalmologyData ManagementMultidisciplinarybiologyQRetinal DegenerationRChartsEuropeAged; Aged 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intravitreal Injections; Italy; Macular Degeneration; Male; Retinal Neovascularization; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual AcuityTreatment OutcomeVertebratesIntravitreal InjectionsRetinal DisordersSensory PerceptionFemalemedicine.symptomAnatomyAngiogenesis InhibitorResearch ArticleEagleComputer and Information SciencesTime FactorBirdsOcular SystemInternal medicineSettore MED/30Growth FactorsmedicineAnimalsEuropean UnionRaptorsEndocrine Physiologybusiness.industryIntravitreal InjectionCognitive PsychologyRetrospective cohort studyMacular degenerationGeriatricsAmniotesCognitive SciencePerceptionbusinessZoologyHeadFollow-Up Studies
researchProduct